276 related articles for article (PubMed ID: 12240789)
1. Effects of fibrates on serum metabolic parameters.
Elisaf M
Curr Med Res Opin; 2002; 18(5):269-76. PubMed ID: 12240789
[TBL] [Abstract][Full Text] [Related]
2. Fibrates, dyslipoproteinaemia and cardiovascular disease.
Watts GF; Dimmitt SB
Curr Opin Lipidol; 1999 Dec; 10(6):561-74. PubMed ID: 10680050
[TBL] [Abstract][Full Text] [Related]
3. Role of fibric acid derivatives in the management of risk factors for coronary heart disease.
Després JP; Lemieux I; Robins SJ
Drugs; 2004; 64(19):2177-98. PubMed ID: 15456334
[TBL] [Abstract][Full Text] [Related]
4. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Fruchart JC; Duriez P
Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
[TBL] [Abstract][Full Text] [Related]
5. Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
Després JP
Am J Cardiol; 2001 Dec; 88(12A):30N-36N. PubMed ID: 11788128
[TBL] [Abstract][Full Text] [Related]
6. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
[TBL] [Abstract][Full Text] [Related]
7. Diabetic dyslipidemia.
Kreisberg RA
Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
[TBL] [Abstract][Full Text] [Related]
8. Current, new and future treatments in dyslipidaemia and atherosclerosis.
Chong PH; Bachenheimer BS
Drugs; 2000 Jul; 60(1):55-93. PubMed ID: 10929930
[TBL] [Abstract][Full Text] [Related]
9. Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations.
Hamilton-Craig I; Kostner KM; Woodhouse S; Colquhoun D
Int J Evid Based Healthc; 2012 Sep; 10(3):181-90. PubMed ID: 22925614
[TBL] [Abstract][Full Text] [Related]
10. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation.
Najib J
Clin Ther; 2002 Dec; 24(12):2022-50. PubMed ID: 12581543
[TBL] [Abstract][Full Text] [Related]
11. Advances in drug treatment of dyslipidemia: focus on atorvastatin.
Davignon J
Can J Cardiol; 1998 May; 14 Suppl B():28B-38B. PubMed ID: 9627539
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of fibrates in postprandial lipemia.
Kolovou GD; Kostakou PM; Anagnostopoulou KK; Cokkinos DV
Am J Cardiovasc Drugs; 2008; 8(4):243-55. PubMed ID: 18690758
[TBL] [Abstract][Full Text] [Related]
14. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
Goa KL; Barradell LB; Plosker GL
Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.
Milionis HJ; Papakostas J; Kakafika A; Chasiotis G; Seferiadis K; Elisaf MS
J Clin Pharmacol; 2003 Aug; 43(8):825-30. PubMed ID: 12953339
[TBL] [Abstract][Full Text] [Related]
16. Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
Devroey D; Velkeniers B; Duquet W; Betz W
Acta Cardiol; 2003 Jun; 58(3):179-84. PubMed ID: 12846506
[TBL] [Abstract][Full Text] [Related]
17. Management of hypercholesterolaemia in the patient with diabetes.
Packard C; Olsson AG
Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
[TBL] [Abstract][Full Text] [Related]
18. Update on the use of fibrates: focus on bezafibrate.
Goldenberg I; Benderly M; Goldbourt U
Vasc Health Risk Manag; 2008; 4(1):131-41. PubMed ID: 18629356
[TBL] [Abstract][Full Text] [Related]
19. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
20. Low serum levels of high-density lipoprotein cholesterol and hypolipidaemic treatment.
Kolovou GD; Cokkinos DV
Curr Med Res Opin; 2002; 18(5):265-8. PubMed ID: 12240788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
